Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)

NCT01803867 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT01803867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01803867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Lead sponsor
Acorda Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
January 31, 2015
Enrollment
72 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis